What Is New - Vasculitis

Take a look at our 'What is new' highlights in Vasculitis!

May 2023

"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial"

Why WIN?

On a continuous hunt to ameliorate the relapse rates of AAVs after induction or remission with rituximab, different solutions such as azathioprine are utilized. In this study, rituximab was proven superior to azathioprine in preventing relapse, following induction of remission with rituximab with a prior history of relapses.

What do you believe would give new players in the armamentarium against relapse after remission in AAVs:?

  • Drug repurposing
  • Drug targeting by biophysics

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

Link to original article: https://ard.bmj.com/content/annrheumdis/82/7/937.full.pdf

 

April 2023

"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update"

Why WIN?

EULAR Recommendations for the management of ANCA-associated vasculitis pose the standard-of-care and point towards the therapeutic future for this disease entity. Previous recommendations are updated, new ones are established and novel therapies take their position in this armamentarium.

What would you vote as the most important novel recommendation for AAV-management?

  • Testing of MPO/PR3-ANCA
  • Mepolizumab
  • T/S prophylaxis

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

 

March 2023

"Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing"

Why WINS?

Limited number of genetic studies have described the genomic landscape of systemic vasculitides, while new weapons in the therapeutic armamentarium are needed. An extended meta-analysis of large cohorts assigned 16 risk loci as vasculitis-relevant. This is an advanced step to bring genetics into clinical practice through drug repurposing.

Do you expect drug repurposing to find merit in treating systemic vasculitides?

  • Yes, it might be a powerful tool
  • No, genetic meta-analyses rarely connect to clinical practice
  • Larger amount of data is still needed.

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

 

February 2023

" Risk factors for serious infections in ANCA-associated vasculitis "

Why WINS?

Severe infections in patients with AAVs are the leading cause of death within the first year of diagnosis, while risk factors are yet to be studied thoroughly. This study emphasizes on the importance of low-dose cycles of antibiotics in AAV patients having received immunosuppressive therapy, showing that B-cell counts are markers for immunocompetence.

Interactive question

What do you believe would you vote as the most important finding of this study?

  1. Therapy scheme
  2. Predictors of infections
  3. B and T cell characteristics in severe infections

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

Jan 2023

" High risk of stroke in ANCA-associated vasculitis-a population-based study "

Why WINS?

AAVs consist of autoimmune phenotypes characterized by inflammation of small blood vessels. Patients with AAV exhibit a higher rate of comorbidities than the general population, including cardiovascular events. This is the first time that stroke risk in AAV patients is thoroughly studied, along with possible predictors and outcomes.

Interactive question

What do you believe would be helpful for elucidating CVD risk in AAVs?

  1. Larger cohorts

  2. Multidisciplinary studies

  3. Relative risk compared to other autoimmune entities?

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

December 2022

" Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial "

Why WINS?

Giant cell arteritis (GCA) is the most prevalent form of systemic vasculitis in adults. Therapeutic choices for ensuring remission in GCA patients are few, thus novel treatments are needed. Preclinical research has implicated GM-CSF in pathophysiology of GCA and mavrilimumab is an efficient GM-CSF receptor antagonist. This study proves that this new therapeutic weapon leads patients with GCA to sustained remission .

Interactive question

What would like to read as the next steps in mavrilimumab-related research?

  1. Pathophysiological mechanism

  2. Mavrilimumab vs Tocilizumab

  3. Other (please comment)

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

Coming in February 2023...

Watch this space!